HK1206423A1 - Oligomeric a in the diagnosis, prognosis, and monitoring of alzheimer's disease - Google Patents
Oligomeric a in the diagnosis, prognosis, and monitoring of alzheimer's disease Download PDFInfo
- Publication number
- HK1206423A1 HK1206423A1 HK15106868.9A HK15106868A HK1206423A1 HK 1206423 A1 HK1206423 A1 HK 1206423A1 HK 15106868 A HK15106868 A HK 15106868A HK 1206423 A1 HK1206423 A1 HK 1206423A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disease
- alzheimer
- monitoring
- prognosis
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610390P | 2012-03-13 | 2012-03-13 | |
| US61/610,390 | 2012-03-13 | ||
| PCT/US2013/031018 WO2013138512A1 (en) | 2012-03-13 | 2013-03-13 | OLIGOMERIC Aβ IN THE DIAGNOSIS, PROGNOSIS, AND MONITORING OF ALZHEIMER'S DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206423A1 true HK1206423A1 (en) | 2016-01-08 |
Family
ID=49161786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106868.9A HK1206423A1 (en) | 2012-03-13 | 2013-03-13 | Oligomeric a in the diagnosis, prognosis, and monitoring of alzheimer's disease |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130273574A1 (https=) |
| EP (1) | EP2825884A4 (https=) |
| JP (1) | JP2015511014A (https=) |
| CN (1) | CN104662423A (https=) |
| CA (1) | CA2867338A1 (https=) |
| HK (1) | HK1206423A1 (https=) |
| WO (1) | WO2013138512A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140128230A (ko) | 2013-04-26 | 2014-11-05 | 한국과학기술연구원 | 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트 |
| EP3316967A4 (en) * | 2015-06-30 | 2018-11-14 | Health Research, Inc. | Diagnostic test for alzheimer's disease based on identification of a proteolytic pathway |
| CN105542005B (zh) * | 2016-02-03 | 2018-11-09 | 大连理工大学 | 一种抗人淀粉样β肽的纳米抗体及其应用 |
| JP6883847B2 (ja) * | 2017-03-30 | 2021-06-09 | 国立大学法人滋賀医科大学 | アミロイドβ蛋白並びにタウ蛋白及び／又はリン酸化タウ蛋白の測定方法 |
| WO2019126395A1 (en) | 2017-12-19 | 2019-06-27 | Chase Therapeutics Corporation | Methods for developing pharmaceuticals for treating neurodegenerative conditions |
| JP7434144B2 (ja) * | 2018-02-27 | 2024-02-20 | 株式会社島津製作所 | ＡＰＰ６６９－ｘのＮ末端を特異的に認識する抗体、及び免疫測定法 |
| CN109187981A (zh) * | 2018-08-01 | 2019-01-11 | 万东山 | 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用 |
| KR101977410B1 (ko) * | 2018-08-22 | 2019-05-10 | 주식회사 피플바이오 | 당뇨병에 대한 신규 바이오마커 및 그의 용도 |
| JP7207517B2 (ja) * | 2019-03-01 | 2023-01-18 | 株式会社島津製作所 | Ａｐｐ６６９－７１１の測定方法、及び測定用キット |
| WO2020198866A1 (en) * | 2019-04-04 | 2020-10-08 | The Royal Institution For The Advancement Of Learning / Mcgill University | USE OF Aß34 TO ASSESS ALZHEIMER'S DISEASE PROGRESSION |
| CN114174830A (zh) * | 2019-07-10 | 2022-03-11 | 托多斯医疗有限公司 | 使用来自临床诊断的阿尔茨海默病受试者的血液样本的阿尔茨海默病的生物标志物 |
| KR20220062287A (ko) * | 2019-08-13 | 2022-05-16 | 워싱턴 유니버시티 | Mtbr 타우 아이소폼 검출 방법 및 이의 용도 |
| WO2021090910A1 (ja) * | 2019-11-08 | 2021-05-14 | セントラル硝子株式会社 | タンパク質凝集塊を検出する分子構造変質剤、その検出方法、医療器具用洗浄剤、土壌洗浄剤及び土壌の洗浄方法 |
| CN111393524B (zh) * | 2020-02-20 | 2022-04-08 | 北京化工大学 | 基于金属标记的阿尔兹海默症脑组织Aβ蛋白的原位检测方法 |
| US20240118281A1 (en) * | 2021-01-11 | 2024-04-11 | University Of Florida Research Foundation, Incorporated | Anticancer compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2006094724A2 (en) * | 2005-03-05 | 2006-09-14 | Abbott Gmbh & Co. Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| TW200844110A (en) * | 2007-01-11 | 2008-11-16 | Univ Marburg Philipps | Diagnosis and treatment of alzheimer's disease and other neurodementing diseases |
| US8022268B2 (en) * | 2007-06-11 | 2011-09-20 | The University Of Zurich | Transgenic animal model for alzheimer's disease |
| CN102936287B (zh) * | 2008-02-08 | 2015-09-09 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
| CN101531717B (zh) * | 2009-04-22 | 2012-07-18 | 北京交通大学 | 抗阿尔茨海默病单克隆抗体及其应用 |
| CA2779565A1 (en) * | 2009-11-24 | 2011-06-03 | Probiodrug Ag | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment |
| JP5747444B2 (ja) * | 2010-04-27 | 2015-07-15 | パナソニックヘルスケア株式会社 | βアミロイドに関連する病的状態の診断補助方法 |
-
2013
- 2013-03-13 CN CN201380021783.5A patent/CN104662423A/zh active Pending
- 2013-03-13 HK HK15106868.9A patent/HK1206423A1/xx unknown
- 2013-03-13 EP EP13760620.8A patent/EP2825884A4/en not_active Withdrawn
- 2013-03-13 US US13/801,844 patent/US20130273574A1/en not_active Abandoned
- 2013-03-13 CA CA2867338A patent/CA2867338A1/en not_active Abandoned
- 2013-03-13 JP JP2015500571A patent/JP2015511014A/ja active Pending
- 2013-03-13 WO PCT/US2013/031018 patent/WO2013138512A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2825884A4 (en) | 2015-11-11 |
| US20130273574A1 (en) | 2013-10-17 |
| EP2825884A1 (en) | 2015-01-21 |
| CN104662423A (zh) | 2015-05-27 |
| JP2015511014A (ja) | 2015-04-13 |
| WO2013138512A1 (en) | 2013-09-19 |
| CA2867338A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1206423A1 (en) | Oligomeric a in the diagnosis, prognosis, and monitoring of alzheimer's disease | |
| WO2015061634A3 (en) | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| WO2013153461A3 (en) | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases | |
| HK1200037A1 (en) | Non-invasive methods of detecting target molecules | |
| WO2012012725A3 (en) | Methods of detecting diseases or conditions using phagocytic cells | |
| EP2539712A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2011143574A3 (en) | Plasma biomarkers for diagnosis of alzheimer's disease | |
| WO2016044338A3 (en) | Methods and systems for diagnosing sleep disorders | |
| WO2011128357A3 (en) | Biomarkers for hypertensive disorders of pregnancy | |
| MX2023005452A (es) | Deteccion de beta amiloide por espectrometria de masas. | |
| AU2010202926B2 (en) | Markers and methods relating to the assessment of Alzheimer's disease | |
| WO2014004889A3 (en) | Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm | |
| WO2014036040A3 (en) | Methods for diagnosis, prognosis and methods of treatment | |
| SA112330754B1 (ar) | طريقة تشخيصية للكشف عن مرض قلبي وعائي | |
| WO2012006056A3 (en) | Ccr6 as a biomarker of alzheimer's disease | |
| WO2013072060A8 (en) | Method for the diagnosis of niemann-pick disease | |
| WO2017029401A8 (en) | Means and methods for diagnosing cardiac disease in a subject | |
| WO2011085057A3 (en) | Methods for detecting insulin autoantibody | |
| WO2011130647A3 (en) | Compositions and methods for characterizing a myopathy | |
| WO2012006394A3 (en) | Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer | |
| WO2014117680A3 (zh) | 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆 | |
| WO2013166153A3 (en) | Methods and compositions for cancer diagnosis | |
| WO2014181215A3 (en) | Method for determining free copper | |
| WO2015091902A3 (en) | Determination of platelet-mirnas in alzheimer's disease |